NYSE:PFEPharmaceuticals
Pfizer Phase 2 Wins Reshape Growth Story In Oncology And Immunology
Pfizer (NYSE:PFE) reported positive randomized Phase 2 results for atirmociclib, its next generation CDK4 inhibitor, in advanced or metastatic breast cancer.
The company also reported positive Phase 2 data for tilrekimig, a trispecific antibody, in moderate to severe atopic dermatitis.
These readouts highlight progress in Pfizer’s late stage pipeline across oncology and immunology at a key point in its corporate transition.
For investors watching NYSE:PFE, these back to back data readouts...